NCT04362670 - Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease. | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

August 11, 2021

Study Completion Date

August 11, 2021

Conditions

Dry Eye Disease

Interventions

DRUG

OTX-CSI

OTX-CSI intracanalicular insert

OTHER

Placebo Vehicle

Hydrogel Vehicle intracanalicular insert

Trial Locations (15)

16066

Ocular Therapeutix, Inc., Cranberry Township

33484

Ocular Therapeutix, Inc., Delray Beach

33773

Ocular Therapeutix, Inc., Largo

38119

Ocular Therapeutix, Inc., Memphis

44115

Ocular Therapeutix, Inc., Cleveland

60046

Ocular Therapeutix, Inc., Lake Villa

63128

Ocular Therapeutix, Inc, St Louis

63131

Ocular Therapeutix, St Louis

64111

Ocular Therapeutix, Inc., Kansas City

78738

Ocular Therapeutix, Lakeway

79902

Ocular Therapeutix, Inc., El Paso

84107

Ocular Therapeutix, Inc., Murray

90301

Ocular Therapeutix, Inc., Inglewood

91345

Ocular Therapeutix, Inc., Mission Hills

92843

Ocular Therapeutix, Inc., Garden Grove